Vaxil Historical Balance Sheet

VXL Stock

CAD 0.01 0.00 0.00%

Trend analysis of Vaxil Bio balance sheet accounts such as Total Assets of 853.8 K, Other Current Liab of 194.2 K, Total Current Liabilities of 92.9 K or Total Stockholder Equity of 1.1 M provides information on Vaxil Bio's total assets, liabilities, and equity, which is the actual value of Vaxil Bio to its prevalent stockholders. By breaking down trends over time using Vaxil Bio balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Vaxil Bio latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Vaxil Bio is a good buy for the upcoming year.

Vaxil Bio Inventory

11,919.05

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vaxil Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About Vaxil Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Vaxil Bio at a specified time, usually calculated after every quarter, six months, or one year. Vaxil Bio Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Vaxil Bio and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Vaxil currently owns. An asset can also be divided into two categories, current and non-current.

Vaxil Bio Balance Sheet Chart

At this time, Vaxil Bio's Other Current Liabilities is fairly stable compared to the past year. Total Stockholder Equity is likely to climb to about 1.1 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 92.9 K in 2025.

Total Assets Other Current Liab Total Current Liabilities Accounts Payable Short Term Debt

Total Assets

Total assets refers to the total amount of Vaxil Bio assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Vaxil Bio books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Vaxil Bio balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Vaxil Bio are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Accounts Payable

An accounting item on the balance sheet that represents Vaxil Bio obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Vaxil Bio are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most accounts from Vaxil Bio's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Vaxil Bio current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vaxil Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

	2022	2023	2024	2025 (projected)
Other Current Liabilities	404.6K	84.9K	97.7K	194.2K
Total Assets	1.5M	976K	1.1M	853.8K

Other Current Liab Total Assets

Vaxil Bio balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Short Long Term Debt Total	Net Tangible Assets	Current Deferred Revenue	Deferred Long Term Liab	Short Long Term Debt	Short Term Debt	Property Plant Equipment	Short Term Investments
Total Assets		0.58	0.3	0.87	-0.47	-0.99	-0.67	0.03	0.99	-0.47	0.99	0.61	0.68	-0.11	-0.49	0.3	0.99	0.66	-0.17	0.78	0.17	-0.08	-0.45	0.01	-0.46	-0.08
Other Current Liab	0.58		0.4	0.41	-0.42	-0.58	-0.35	-0.18	0.56	-0.42	0.56	0.4	0.3	0.41	-0.36	0.37	0.6	0.26	-0.01	0.38	0.23	0.05	-0.32	0.17	-0.51	0.05
Total Current Liabilities	0.3	0.4		-0.2	-0.24	-0.29	-0.5	0.82	0.3	-0.24	0.3	0.45	0.17	0.27	0.03	1.0	0.33	0.27	0.5	-0.04	0.47	0.32	-0.52	0.45	0.06	0.32
Total Stockholder Equity	0.87	0.41	-0.2		-0.4	-0.87	-0.46	-0.39	0.86	-0.4	0.86	0.41	0.66	-0.25	-0.56	-0.21	0.85	0.55	-0.44	0.85	-0.06	-0.34	-0.22	-0.23	-0.55	-0.34
Property Plant And Equipment Net	-0.47	-0.42	-0.24	-0.4		0.56	0.73	-0.04	-0.56	1.0	-0.56	-0.45	-0.72	-0.11	0.5	-0.22	-0.58	-0.68	-0.14	-0.67	-0.69	0.32	0.88	-0.44	0.84	0.32
Net Debt	-0.99	-0.58	-0.29	-0.87	0.56		0.71	-0.02	-0.99	0.56	-0.99	-0.6	-0.72	0.16	0.49	-0.28	-0.99	-0.69	0.16	-0.81	-0.22	0.12	0.52	-0.04	0.53	0.12
Retained Earnings	-0.67	-0.35	-0.5	-0.46	0.73	0.71		-0.35	-0.72	0.73	-0.72	-0.63	-0.91	0.14	0.59	-0.5	-0.72	-0.86	-0.23	-0.78	-0.52	0.27	0.85	-0.33	0.54	0.27
Accounts Payable	0.03	-0.18	0.82	-0.39	-0.04	-0.02	-0.35		0.03	-0.04	0.03	0.31	0.05	0.06	0.23	0.83	0.04	0.15	0.44	-0.21	0.35	0.24	-0.39	0.32	0.34	0.24
Cash	0.99	0.56	0.3	0.86	-0.56	-0.99	-0.72	0.03		-0.56	1.0	0.6	0.72	-0.17	-0.49	0.29	1.0	0.72	-0.13	0.8	0.24	-0.08	-0.52	0.06	-0.52	-0.08
Non Current Assets Total	-0.47	-0.42	-0.24	-0.4	1.0	0.56	0.73	-0.04	-0.56		-0.56	-0.45	-0.72	-0.11	0.5	-0.22	-0.58	-0.68	-0.14	-0.67	-0.69	0.32	0.88	-0.44	0.84	0.32
Cash And Short Term Investments	0.99	0.56	0.3	0.86	-0.56	-0.99	-0.72	0.03	1.0	-0.56		0.6	0.72	-0.17	-0.49	0.29	1.0	0.72	-0.13	0.8	0.24	-0.08	-0.52	0.06	-0.52	-0.08
Net Receivables	0.61	0.4	0.45	0.41	-0.45	-0.6	-0.63	0.31	0.6	-0.45	0.6		0.51	0.15	-0.14	0.44	0.63	0.48	-0.05	0.5	0.36	-0.06	-0.58	0.11	-0.33	-0.06
Common Stock Shares Outstanding	0.68	0.3	0.17	0.66	-0.72	-0.72	-0.91	0.05	0.72	-0.72	0.72	0.51		-0.27	-0.74	0.16	0.72	0.85	-0.02	0.91	0.29	-0.54	-0.69	0.07	-0.69	-0.54
Other Current Assets	-0.11	0.41	0.27	-0.25	-0.11	0.16	0.14	0.06	-0.17	-0.11	-0.17	0.15	-0.27		-0.14	0.25	-0.08	-0.27	0.0	-0.22	0.19	0.19	-0.03	0.16	-0.13	0.19
Other Stockholder Equity	-0.49	-0.36	0.03	-0.56	0.5	0.49	0.59	0.23	-0.49	0.5	-0.49	-0.14	-0.74	-0.14		0.05	-0.51	-0.53	0.14	-0.73	-0.05	0.48	0.35	0.06	0.64	0.48
Total Liab	0.3	0.37	1.0	-0.21	-0.22	-0.28	-0.5	0.83	0.29	-0.22	0.29	0.44	0.16	0.25	0.05		0.32	0.26	0.53	-0.05	0.49	0.32	-0.52	0.49	0.11	0.32
Total Current Assets	0.99	0.6	0.33	0.85	-0.58	-0.99	-0.72	0.04	1.0	-0.58	1.0	0.63	0.72	-0.08	-0.51	0.32		0.71	-0.13	0.8	0.26	-0.08	-0.54	0.07	-0.54	-0.08
Common Stock	0.66	0.26	0.27	0.55	-0.68	-0.69	-0.86	0.15	0.72	-0.68	0.72	0.48	0.85	-0.27	-0.53	0.26	0.71		0.08	0.78	0.35	-0.25	-0.67	0.16	-0.55	-0.25
Short Long Term Debt Total	-0.17	-0.01	0.5	-0.44	-0.14	0.16	-0.23	0.44	-0.13	-0.14	-0.13	-0.05	-0.02	0.0	0.14	0.53	-0.13	0.08		-0.18	0.59	0.1	-0.4	0.86	0.19	0.1
Net Tangible Assets	0.78	0.38	-0.04	0.85	-0.67	-0.81	-0.78	-0.21	0.8	-0.67	0.8	0.5	0.91	-0.22	-0.73	-0.05	0.8	0.78	-0.18		0.26	-0.55	-0.58	0.05	-0.7	-0.55
Current Deferred Revenue	0.17	0.23	0.47	-0.06	-0.69	-0.22	-0.52	0.35	0.24	-0.69	0.24	0.36	0.29	0.19	-0.05	0.49	0.26	0.35	0.59	0.26		-0.07	-0.86	0.88	-0.28	-0.07
Deferred Long Term Liab	-0.08	0.05	0.32	-0.34	0.32	0.12	0.27	0.24	-0.08	0.32	-0.08	-0.06	-0.54	0.19	0.48	0.32	-0.08	-0.25	0.1	-0.55	-0.07		0.23	0.02	0.39	1.0
Short Long Term Debt	-0.45	-0.32	-0.52	-0.22	0.88	0.52	0.85	-0.39	-0.52	0.88	-0.52	-0.58	-0.69	-0.03	0.35	-0.52	-0.54	-0.67	-0.4	-0.58	-0.86	0.23		-0.64	0.55	0.23
Short Term Debt	0.01	0.17	0.45	-0.23	-0.44	-0.04	-0.33	0.32	0.06	-0.44	0.06	0.11	0.07	0.16	0.06	0.49	0.07	0.16	0.86	0.05	0.88	0.02	-0.64		-0.05	0.02
Property Plant Equipment	-0.46	-0.51	0.06	-0.55	0.84	0.53	0.54	0.34	-0.52	0.84	-0.52	-0.33	-0.69	-0.13	0.64	0.11	-0.54	-0.55	0.19	-0.7	-0.28	0.39	0.55	-0.05		0.39
Short Term Investments	-0.08	0.05	0.32	-0.34	0.32	0.12	0.27	0.24	-0.08	0.32	-0.08	-0.06	-0.54	0.19	0.48	0.32	-0.08	-0.25	0.1	-0.55	-0.07	1.0	0.23	0.02	0.39

Click cells to compare fundamentals

Vaxil Bio Account Relationship Matchups

Vaxil Bio balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	1.7M	2.3M	1.5M	976K	1.1M	853.8K
Other Current Liab	260K	584.4K	404.6K	84.9K	97.7K	194.2K
Total Current Liabilities	857K	585K	405K	85K	97.8K	92.9K
Total Stockholder Equity	804K	1.7M	1.1M	891K	1.0M	1.1M
Net Debt	(1.5M)	(2.2M)	(1.5M)	(938K)	(844.2K)	(886.4K)
Retained Earnings	(17.5M)	(18.5M)	(19.1M)	(19.4M)	(17.4M)	(16.6M)
Accounts Payable	588K	559.0	394.0	85.0	97.75	92.86
Cash	83K	1.5M	2.2M	938K	1.1M	665.5K
Cash And Short Term Investments	83K	1.5M	2.2M	938K	1.1M	665.5K
Net Receivables	33K	35K	20K	19K	21.9K	21.4K
Common Stock Shares Outstanding	101.7M	136.1M	137.0M	137.0M	157.5M	165.4M
Liabilities And Stockholders Equity	1.7M	2.3M	1.5M	976K	1.1M	853.8K
Other Current Assets	91K	7K	11K	38.0	34.2	32.49
Other Stockholder Equity	1.9M	816K	755K	358K	324K	0.0
Total Liab	857K	585K	405K	85K	97.8K	92.9K
Total Current Assets	1.6M	2.3M	1.5M	976K	1.1M	723.9K
Accumulated Other Comprehensive Income	3.7M	3.8M	3.8M	4.2M	4.8M	5.0M
Net Tangible Assets	435K	(583K)	804K	1.7M	2.0M	2.1M
Property Plant Equipment	62K	95K	27K	2K	1.8K	1.7K
Net Invested Capital	804K	1.7M	1.1M	891K	1.0M	612.2K
Net Working Capital	777K	1.7M	1.1M	891K	1.0M	573.9K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Vaxil Stock Analysis

When running Vaxil Bio's price analysis, check to measure Vaxil Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxil Bio is operating at the current time. Most of Vaxil Bio's value examination focuses on studying past and present price action to predict the probability of Vaxil Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxil Bio's price. Additionally, you may evaluate how the addition of Vaxil Bio to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Vaxil Historical Balance Sheet

Vaxil Bio Inventory

11,919.05

About Vaxil Balance Sheet Analysis

Vaxil Bio Balance Sheet Chart

Total Assets

Total Current Liabilities

Accounts Payable

Vaxil Bio balance sheet Correlations

Vaxil Bio Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Vaxil Bio balance sheet Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Vaxil Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Liab	+ 1.0	Total Current Liabilities
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments
Short Term Investments	+ 1.0	Deferred Long Term Liab

Total Current Assets	- 0.99	Net Debt
Cash And Short Term Investments	- 0.99	Net Debt
Cash	- 0.99	Net Debt
Net Debt	- 0.99	Total Assets
Common Stock Shares Outstanding	- 0.91	Retained Earnings
Net Debt	- 0.87	Total Stockholder Equity